keyword
MENU ▼
Read by QxMD icon Read
search

Unresectability

keyword
https://www.readbyqxmd.com/read/30343559/non-enhancing-gliomas-does-intraoperative-ultrasonography-improve-resections
#1
Aliasgar V Moiyadi, Prakash Shetty, Robin John
Purpose: Non-enhancing diffuse gliomas are a challenging surgical proposition. Delineation of tumour extent on preoperative imaging and intraoperative visualization are often difficult. Methods: We retrospectively analyzed all cases of non-enhancing gliomas that were operated on using navigated 3-dimensional ultrasonography (US). Tumour delineation (good, moderate, or poor) on preoperative magnetic resonance imaging (MRI) and intraoperative US was compared. Post-resection US findings with respect to residual tumour status were compared to the postoperative imaging findings...
July 29, 2018: Ultrasonography
https://www.readbyqxmd.com/read/30343254/folfirinox-as-induction-treatment-in-rectal-cancer-patients-with-synchronous-metastases-results-of-the-ffcd-1102-phase-ii-trial
#2
J B Bachet, O Lucidarme, C B Levache, E Barbier, J L Raoul, T Lecomte, C Desauw, F Brocard, S Pernot, G Breysacher, J P Lagasse, F Di Fiore, P L Etienne, O J M Dupuis, A Aleba, C Lepage, J Taieb
AIM OF THE STUDY: The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. PATIENTS AND METHODS: Chemotherapy-naïve patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus...
October 18, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/30341417/optimizing-the-outcomes-of-pancreatic-cancer-surgery
#3
REVIEW
Oliver Strobel, John Neoptolemos, Dirk Jäger, Markus W Büchler
Pancreatic cancer is likely to become the second most frequent cause of cancer-associated mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy currently provides the only chance of long-term survival. However, only 10-20% of patients with pancreatic cancer are diagnosed with localized, surgically resectable disease. The majority of patients present with metastatic disease and are not candidates for surgery, while surgery remains underused even in those with resectable disease owing to historical concerns regarding safety and efficacy...
October 19, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30338364/transvenous-pulmonary-chemoembolization-tpce-for-palliative-or-neoadjuvant-treatment-of-lung-metastases
#4
Thomas J Vogl, Ahmed I A Mekkawy, Duaa B Thabet, Mostafa El-Sharkaway, Hosam M Kamel, Moritz H Albrecht, Nagy N N Naguib, Afaf Hassan
PURPOSE: To retrospectively evaluate tumor response, local tumor control, and patient survival after the treatment of pulmonary metastases using transpulmonary chemoembolization (TPCE) in palliative and neoadjuvant intent. MATERIALS AND METHODS: One hundred forty-three patients (mean age 56.7 ± 13.4 years) underwent repetitive TPCE (mean number of sessions 5.8 ± 2.9) between June 2005 and April 2017 for the treatment of unresectable lung metastases, not responding to systemic chemotherapy...
October 18, 2018: European Radiology
https://www.readbyqxmd.com/read/30337098/early-pancreatic-cancer-the-role-of-endoscopic-ultrasound-with-or-without-tissue-acquisition-in-diagnosis-and-staging
#5
REVIEW
Pedro Moutinho-Ribeiro, Julio Iglesias-Garcia, Rui Gaspar, Guilherme Macedo
Pancreatic cancer (PC) is one of the deadliest cancers with a 5-year overall survival of less than 6%. Due to its insidious clinical course and unspecific symptoms, the diagnosis is usually late, with only 15-20% patients presenting with potentially curable disease. It is, therefore, extremely important to identify patients with PC at early stages of the disease when tumors may be amenable to surgical resection. For unresectable and borderline resectable PC it is consensual to perform a biopsy to have a cyto/histological confirmation of malignancy before treatment...
October 5, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/30334945/microwave-ablation-combined-with-transcatheter-arterial-chemoembolization-is-effective-for-treating-unresectable-hepatoblastoma-in-infants-and-children
#6
Yizhou Jiang, Shaoyi Zhou, Gang Shen, Hua Jiang, Jing Zhang
The present study is to evaluate the feasibility and efficacy of microwave ablation (MWA) combined with transcatheter arterial chemoembolization (TACE) in the treatment for unresectable hepatoblastoma in infants and children. A total of 17 patients with PRETEXT stage III and IV hepatoblastoma that was unresectable by conventional resection were included in the present study. The patients were treated with TACE, MWA, and chemotherapy. All cases were diagnosed by computed tomography (CT) and liver tumor biopsy before TACE procedure...
October 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/30328072/outcomes-and-prognostic-factors-of-spontaneously-ruptured-hepatocellular-carcinoma
#7
Wei Zhang, Zhi-Wei Zhang, Bi-Xiang Zhang, Zhi-Yong Huang, Wan-Guang Zhang, Hui-Fang Liang, Xiao-Ping Chen
BACKGROUND: Spontaneous tumor rupture is a rare and life-threatening complication of hepatocellular carcinoma (HCC). The best treatment strategy remains unclear. METHODS: The clinical data of 137 patients with spontaneously ruptured HCC from 2010 to 2015 were reviewed retrospectively. We investigated the outcome and prognostic factors of various treatment strategies. RESULTS: Of the 137 patients, 53, 45, 3, and 36 patients underwent transcatheter arterial chemoembolization (TACE) alone, liver resection (LR) (LR alone or TACE + LR), surgical hemostasis, and conservative therapy...
September 4, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/30327398/protocol-for-the-strong-trial-stereotactic-body-radiation-therapy-following-chemotherapy-for-unresectable-perihilar-cholangiocarcinoma-a-phase-i-feasibility-study
#8
Merel S Koedijk, Ben J M Heijmen, Bas Groot Koerkamp, Ferry A L M Eskens, Dave Sprengers, Jan-Werner Poley, Dik C van Gent, Luc J W van der Laan, Bronno van der Holt, François E J A Willemssen, Alejandra Méndez Romero
INTRODUCTION: For patients with perihilar cholangiocarcinoma (CCA), surgery is the only treatment modality that can result in cure. Unfortunately, in the majority of these patients, the tumours are found to be unresectable at presentation due to either local invasive tumour growth or the presence of distant metastases. For patients with unresectable CCA, palliative chemotherapy is the standard treatment yielding an estimated median overall survival (OS) of 12-15.2 months. There is no evidence from randomised trials to support the use of stereotactic body radiation therapy (SBRT) for CCA...
October 15, 2018: BMJ Open
https://www.readbyqxmd.com/read/30326958/the-role-of-induction-chemotherapy-followed-by-surgery-in-unresectable-stage-ivb-laryngeal-and-hypopharyngeal-cancers-a-case-series
#9
Pichit Sittitrai, Donyarat Reunmarkkaew, Saisaward Chaiyasate
BACKGROUND: The purpose of this study was to evaluate the benefit of induction chemotherapy followed by surgery in locally advanced unresectable stage IVb laryngeal and hypopharyngeal squamous cell carcinoma (LHSCC). METHODS: Data of patients with stage IVb LHSCC who received induction chemotherapy for the purpose of tumor resection between January 2007 and January 2016 were retrospectively collected. Definitive surgery with postoperative adjuvant therapy was performed in patients whose tumors became resectable (resectable group)...
October 16, 2018: Journal of Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/30326507/antiphospholipid-syndrome-following-pembrolizumab-treatment-of-stage-iiib-unresectable-melanoma
#10
Adrien Sanchez, Henri Montaudie, Pierre Bory, Xavier Belgodere, Thierry Passeron, Jean Philippe Lacour, Alexandra Picard
No abstract text is available yet for this article.
September 19, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/30326370/evaluation-of-the-prognostic-value-of-the-new-ajcc-8th-edition-staging-system-for-patients-with-pancreatic-adenocarcinoma-a-need-to-subclassify-stage-iii
#11
Meiying Song, Seung Bae Yoon, In Seok Lee, Tae Ho Hong, Ho Joong Choi, Moon Hyung Choi, Myung Ah Lee, Eun Sun Jung, Myung-Gyu Choi
BACKGROUND: There have been several proposed changes for the 8th edition of the American Joint Commission on Cancer (AJCC) for pancreatic adenocarcinoma. The aim of this study was to evaluate the prognostic value of the new staging system for patients with pancreatic adenocarcinoma, especially in stage III patients. METHODS: We analysed the data of patients newly diagnosed with pancreatic adenocarcinoma between 2008 and 2016 at our hospital. Patients were staged according to 7th edition AJCC criteria, as well as the new 8th edition staging system...
October 13, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/30324485/first-line-gemcitabine-and-nab-paclitaxel-chemotherapy-for-localized-pancreatic-ductal-adenocarcinoma
#12
Pat Gulhati, Laura Prakash, Matthew H G Katz, Xuemei Wang, Milind Javle, Rachna Shroff, David Fogelman, Jeffrey E Lee, Ching-Wei D Tzeng, Jeffrey H Lee, Brian Weston, Eric Tamm, Priya Bhosale, Eugene J Koay, Anirban Maitra, Huamin Wang, Robert A Wolff, Gauri R Varadhachary
BACKGROUND: Preoperative chemotherapy provides early treatment of micro-metastases and guaranteed delivery of all components of multimodality therapy for localized pancreatic ductal adenocarcinoma (PDAC). For locally advanced (LA) PDAC, induction chemotherapy is the standard of care. This study evaluated the use of gemcitabine and nab-paclitaxel (Gem/nab-P) as first-line therapy for localized PDAC. METHODS: Clinicopathologic features, treatment, and outcomes were evaluated for 99 patients with localized PDAC...
October 15, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/30323733/a-highly-advanced-gastric-cancer-maintaining-a-clinical-complete-response-after-chemoradiotherapy-comprising-s-1-and-cisplatin
#13
Masahiro Yura, Tsunehiro Takahashi, Kazumasa Fukuda, Rieko Nakamura, Norihito Wada, Junichi Fukada, Hirofumi Kawakubo, Hiroya Takeuchi, Naoyuki Shigematsu, Yuko Kitagawa
We report a patient with highly advanced gastric carcinoma who was treated successfully with chemoradiotherapy (CRT) comprising S-1 and cisplatin. The patient was a 71-year-old male who was diagnosed with advanced gastric carcinoma by esophagogastroduodenoscopy (EGD) by medical examination. EGD demonstrated type 3 advanced gastric carcinoma in the posterior wall of the upper gastric body. An abdominal computed tomography (CT) scan showed that the gastric wall was thickened due to gastric primary tumor, and large lymph nodes (LNs) including the lesser curvature LN, anterosuperior LN along the common hepatic artery and some para-aortic LNs were detected...
September 2018: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/30322402/radiofrequency-ablation-versus-resection-for-technically-resectable-colorectal-liver-metastasis-a-propensity-score-analysis
#14
Li-Jun Wang, Zhong-Yi Zhang, Xiao-Luan Yan, Wei Yang, Kun Yan, Bao-Cai Xing
BACKGROUND: Liver resection is the first-line treatment for patients with resectable colorectal liver metastasis (CRLM), while radiofrequency ablation (RFA) can be used for small unresectable CRLM because of disease extent, poor anatomical location, or comorbidities. However, the long-term outcomes are unclear for RFA treatment in resectable CRLM. This study aimed to compare the recurrence rates and prognosis between resectable CRLM patients receiving either liver resection or RFA. METHODS: Consecutive patients who underwent RFA or hepatic resection from November 2010 to December 2015 were assigned in this retrospective study...
October 15, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/30320362/targeting-lrh%C3%A2-1-in-hepatoblastoma-cell-lines-causes-decreased-proliferation
#15
Jingling Jin, Junliang Jin, Sarah E Woodfield, Roma H Patel, Nan Ge Jin, Yan Shi, Bin Liu, Wenjing Sun, Xiangmei Chen, Yang Yu, Sanjeev A Vasudevan
Hepatoblastoma is the most common malignant liver tumor in children. Since it is often unresectable and exhibits drug resistance, the treatment of advanced hepatoblastoma is challenging. The orphan nuclear receptor liver receptor homolog‑1 (LRH‑1) serves prominent roles in malignancy; however, to the best of our knowledge, the role of LRH‑1 in hepatoblastoma remains unknown. In the present study, human hepatoblastoma cell lines were analyzed; the mRNA and protein expression levels of LRH‑1 were significantly higher in HepG2 and HuH6 cells compared with those in HepT1 cells and control THLE‑2 cells...
October 15, 2018: Oncology Reports
https://www.readbyqxmd.com/read/30318515/galunisertib-plus-gemcitabine-vs-gemcitabine-for-first-line-treatment-of-patients-with-unresectable-pancreatic-cancer
#16
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Martin Fuchs, Jorg Trojan, Helmut Oettle, Mark Kozloff, Ann Cleverly, Claire Smith, Shawn T Estrem, Ivelina Gueorguieva, Michael M F Lahn, Al Blunt, Karim A Benhadji, Josep Tabernero
BACKGROUND: Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. placebo in patients with unresectable pancreatic cancer was determined. METHODS: This was a two-part, multinational study: phase 1b was a non-randomised, open-label, multicentre, and dose-escalation study; phase 2 was a randomised, placebo- and Bayesian-augmented controlled, double-blind study in patients with locally advanced or metastatic pancreatic adenocarcinoma considered candidates for first-line chemotherapy with gemcitabine...
October 15, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/30316684/folfcis-treatment-and-genomic-correlates-of-response-in-advanced-anal-squamous-cell-cancer
#17
Sebastian Mondaca, Walid K Chatila, David Bates, Jaclyn F Hechtman, Andrea Cercek, Neil H Segal, Zsofia K Stadler, Anna M Varghese, Ritika Kundra, Marinela Capanu, Jinru Shia, Nikolaus Schultz, Leonard Saltz, Rona Yaeger
BACKGROUND: Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC. PATIENTS AND METHODS: We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy - essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin - in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers...
September 21, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/30314681/small-molecule-tyrosine-kinase-inhibitors-and-pancreatic-cancer-trials-and-troubles
#18
REVIEW
Bhaskar Venkata Kameswara Subrahmanya Lakkakula, Batoul Farran, Saikrishna Lakkakula, Sujatha Peela, Nagendra Sastry Yarla, Pallaval Veera Bramhachari, Mohammad Amjad Kamal, Madhu Sudhana Saddala, Ganji Purnachandra Nagaraju
Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs...
October 9, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/30311050/comparison-of-health-related-quality-of-life-after-transarterial-chemoembolization-and-transarterial-radioembolization-in-patients-with-unresectable-hepatocellular-carcinoma
#19
T Kirchner, S Marquardt, T Werncke, M M Kirstein, T Brunkhorst, F Wacker, A Vogel, Thomas Rodt
PURPOSE: The purpose of this study was to compare quality of life (QoL) after two different transarterial therapies [transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)] for patients with unresectable hepatocellular carcinoma (HCC) to assess tumor therapy in palliative situation additional to traditional aims like survival or image response. MATERIAL AND METHODS: QoL was evaluated with two validated questionnaires (EORTC QLQ-30 and EORTC HCC18) before and 14d after treatment in 94 initial therapies (TACE n = 67; TARE n = 27)...
October 11, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/30309645/cholangiocarcinoma-and-gallbladder-cases-an-expert-panel-case-based-discussion
#20
REVIEW
Pamela J Boimel, Kim Reiss Binder, Theodore S Hong, Mary Feng, Edgar Ben-Josef
Cholangiocarcinoma and gallbladder malignancies are aggressive gastrointestinal malignancies with management dependent on resectability, comorbidities, and location. A multidisciplinary discussion with medical oncologists, radiation oncologists, and surgeons is necessary to determine the optimal treatment approach for each patient. Surgical resection offers the best chance for a long-term cure. Recent studies, such as the phase II SWOG S0809 and the phase III BILCAP study have highlighted the importance of adjuvant treatment with radiation therapy and chemotherapy, respectively, in resected disease...
October 2018: Seminars in Radiation Oncology
keyword
keyword
161552
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"